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Introduction: Tumor-infiltrating lymphocytes (TILs) might be associated with host-cell mediated im-
munity, which could be partly reflected by peripheral blood cell counts. In addition, lymphocyte-
predominant breast cancer (LPBC), which was defined as tumors having high TIL levels, showed a
favorable prognosis among triple-negative breast cancer or HER2-positive breast cancer. We aimed to
investigate whether peripheral blood cell counts are associated with LPBC.
Methods: We evaluated the percentage of stromal TILs in breast cancer patients who underwent primary
surgery, using the standardized methodology proposed by the international TIL Working Group.
Lymphocyte-predominant breast cancer (LPBC) was defined as tumors having high TIL levels (50%).
Peripheral blood cell counts including absolute neutrophil counts (ANC), absolute lymphocyte counts
(ALC) and neutrophil-to-lymphocyte ratio (NLR) was obtained from pretreatment laboratory data.
Result: Of the 810 patients, 132 (16.3%) had LPBC, and 678 (83.7%) had non-LBPC. In a comparison of 3
markers of peripheral blood counts, LPBC had a significantly lower mean ANC than non-LPBC (3,304 vs.
3,564; P¼ 0.023), but the other means were not different. In multivariable analysis, each 1K increment in
ANC corresponded to an odds ratio of 0.790 (95% CI, 0.642 to 0.971) for LPBC. In the ER-negative and
high-Ki67 subgroups identified by interaction tests, significant inverse correlations between continuous
ANC and TILs were noted.
Conclusion: Low peripheral ANC could be linked with LPBC, supporting the hypothesis that systemic
immune cell counts might be associated with the tumor-immune microenvironment.
© 2019 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Leukocytes, or white blood cells (WBCs), are involved in both
immune and inflammatory processes. There are two primary types
of leukocytes: granular- and agranular-. Granular leukocytes
include eosinophils, neutrophils, and basophils, while agranular
leukocytes, which lack cytoplasmic granules, include monocytes
and lymphocytes. In general, leukocytes play a major role in the
immune response to macromolecules released from abnormal cellsry, Gangnam Severance Hos-
nju-ro, Gangnam-Gu, Seoul
s article under the CC BY-NC-ND liand microorganisms.
Increasing evidence has shown that blood cell counts or ratio,
such as the absolute neutrophil counts (ANC), absolute lymphocyte
counts (ALC), and neutrophil-to-lymphocyte ratio (NLR), are inde-
pendent prognostic and predictive markers in several cancers
[1e14]. Moreover, NLR could be addressed as a biomarker for the
degree of natural and adaptive immune response against tumor
[1e3,11,15e17].
While these leukocyte parameters are systemic biomarkers of
host immunity, tumor-infiltrating lymphocytes (TILs) are tissue-
based biomarkers for adaptive immune response. TILs, which are
directly measured in malignant tissues, have been highlighted as a
biomarker for predicting treatment response to chemotherapy in
patients with breast cancer [1,4,15e19]. In addition, lymphocyte-
predominant breast cancer (LPBC), which was defined as tumorscense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Baseline characteristics of two groups with or without lymphocyte-predominant
breast cancer (LPBC).
LPBC; n¼ 132 (%) Non-LPBC; n¼ 678 (%) p value
Age (years) 52.36± 10.75 52.50± 10.80 0.891
Histology 0.045
IDC 117 (88.6) 552 (81.4)
non-IDC 15 (11.4) 126 (18.6)
ER <0.001
Positive 66 (50) 603 (88.9)
Negative 66 (50) 75 (11.1)
PR <0.001
Positive 44 (33.3) 530 (78.2)
Negative 88 (66.7) 148 (21.8)
HER2b,c <0.001
Positive 64 (48.5) 89 (13.1)
Negative 67 (50.8) 589 (86.9)
T stage 0.220
1 87 (65.9) 461 (68.0)
2 44 (33.3) 196 (28.9)
3 1 (0.8) 21 (3.1)
N stage 0.209
0 113 (85.6) 529 (78.0)
1 17 (12.9) 122 (18.0)
2 1 (0.8) 19 (2.8)
3 1 (0.8) 8 (1.2)
TNM Stagea 0.197
I 77 (58.3) 391 (57.7)
II 53 (40.2) 253 (37.3)
III 2 (1.5) 34 (5.0)
HGb <0.001
I 2 (1.5) 158 (23.3)
II 66 (50) 441 (65.0)
III 49 (37.1) 65 (9.6)
Ki67b <0.001
<20% 28 (21.2) 489 (72.1)
20% 101 (76.5) 185 (27.3)
Subtypes <0.001
Luminal/HER2() 38 (28.8) 548 (80.8)
HER2(þ) 64 (48.5) 89 (13.1)
TNBC 30 (22.7) 41 (6.0)
ANC (1000 cells/mm3) 3.30± 0.99 3.65± 1.24 0.009
ALC (1000 cells/mm3) 1.95± 0.52 1.98± 0.61 0.526
NLR 1.42± 0.87 1.44± 1.04 0.812
IDC, invasive ductal carcinoma; ER, estrogen receptor; PR, progesterone receptor;
HER-2, human epidermal growth factor receptor-2; HG, histologic grade; TNBC,
triple negative breast cancer; ANC, absolute neutrophil count; ALC, absolute
lymphocyte count; NLR, neutrophil to lymphocyte ratio.
a AJCC stage was performed based on 7th edition.
b Missing value.
c HER-2 positive was defined by 3 þ on immunohistochemistry or amplification
on fluorescence in situ hybridization.
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negative breast cancer or HER2-positive breast cancer.
The level of TILs is directly influenced by the host immune
system because it is a product of tumor-host immune interactions.
Thus, it is worthwhile to explore the relationship between TILs and
host immunity. Among the various assessing methods, peripheral
blood cell count is the easiest non-invasiveness and repetition tool
for assessing host immunity function. However, the relationship
between TILs and blood cell counts in patients with breast cancer is
unclear.
Here, we aimed to evaluate the association between LPBC and
blood cell counts including ALC, ANC, and NLR in treatment-naïve
breast cancer. After we found a significant association between ANC




From August 2016 to July 2018, we enrolled patients with
invasive breast cancer who underwent primary breast surgery
without preoperative chemotherapy in Gangnam Severance Breast
Cancer Center. Those who have (i) a history of transfusion within 3
months, (ii) active infection, (iii) acute/chronic inflammatory dis-
ease, and (iv) autoimmune disease were excluded. Clinical data
including age at the time of surgery, histologic grade (HG), tumor
size, lymph node status, estrogen receptor (ER) status, progesterone
receptor (PR) status, human epidermal growth factor receptor-2
(HER2) status, and Ki-67 labelling index were collected from the
medical database. Peripheral blood cell counts were used to
determine the ANC, ALC, and NLR. The TNM stage was classified
based on the American Joint Committee on Cancer, 7th edition, and
tumor grade was determined using the modified Scarf-Bloo-
mereRichardson grading system.
Assessment of TIL scores and definition of LPBC
The TIL score was evaluated as previously described [20,21]. A
pathologist (YJC) blinded to the clinical information reviewed the
histologic features using hematoxylin and eosin (H&E) staining.
Briefly, the TIL level was evaluated in treatment-naïve surgical
specimens and was scored according to the standardized meth-
odology proposed by the international TIL Working Group [18].
Stromal TILs were evaluated according to the guideline. The tumor
area, defined by invasive tumor cells, was identified. All mono-
nuclear cells, including lymphocytes and plasma cells but not
polymorphonuclear leukocytes, were counted. The area outside the
tumor border, around the intraductal component, and normal
lobules were excluded. Within the tumor border, areas showing
crush artifacts and necrosis were also excluded. For each case, the
average TIL was counted on a representative section of the whole
tumor, and the average score was reported as a percentage.
In this study, lymphocyte-predominant breast cancer (LPBC)
was defined as tumors having high TIL levels (50%). The cut-off
point of 50% was set according to previous studies using treat-
ment-naïve surgical specimen [15,22].
Immunohistochemistry and interpretation
ER (1:100 clone 6F11; Novocastra, Newcastle upon Tyne, UK), PR
(clone 16; Novocastra), HER2 (4B5 rabbit monoclonal antibody;
Ventana Medical Systems, Tucson, AZ, USA), and Ki-67 (MIB-1;
Dako, Glostrup, Denmark) were stained using formalin fixed
paraffin-embedded tissue sections as previously described [23,24].ER positivity and PR expression on immunohistochemistry were
defined according to the modified Allred system. In our study, ER
and PR positivity were defined as an Allred score 3. HER2 staining
was analyzed according to the American Society of Clinical
Oncology/College of American Pathologists guidelines [25]. HER2
immunostaining was considered positive when strong membra-
nous staining (3þ) was observed, whereas 0 and 1þwere regarded
as negative. The cases showing 2 þ HER2 expression were further
evaluated for HER2 amplification via silver in situ hybridization.
Nuclear positivity of Ki-67 staining was evaluated, and the per-
centage of positive tumor cell (range 0%e100%) was reported as the
Ki-67 labeling index. For the breast cancer subtyping, the following
definitions were used: i) luminal/HER2(): ER positive and/or PR
positive, and HER2 negative; ii) HER2(þ): HER2 positive regardless
of ER and PR status; iii) TNBC: ER negative, PR negative, and HER2
negative.
Complete blood count examination
Blood cell counts including hemoglobin, platelet, WBC, ANC,
Fig. 1. Comparisons of peripheral blood markers according to LPBC. We compared means of peripheral blood count including absolute neutrophil count (ANC), absolute
lymphocyte count (ALC), and neutrophil to lymphocyte ratio (NLR) between LPBC and non-LPBC (A) The mean ANC of the LPBC group was significantly higher than that of the non-
LPBC (P¼ 0.023; Student’s t-test). (B&C) Means of ALC and NLR did not differ between two groups (P¼ 0.528 and P¼ 0.099, respectively; Student’s t-test).
C.I. Yoon et al. / The Breast 50 (2020) 141e148 143ALC, neutrophil percentage, lymphocyte percentage, and NLR were
obtained from pretreatment laboratory data. Blood samples were
collected during the treatment-naïve state after diagnosis. WBC
counts were performed at the Department of Laboratory Medicine,
Gangnam Severance Hospital using an automated counting ma-
chine (Sysmex XN-series; Kobe, Japan). The Wright or Mary-
Grinewald-Giemsa technique was used to determine the differen-
tial count; briefly, a drop of blood was thinly spread over a glass-
slide, air dried, and stained with Romanowsky stain. WBC differ-
entiation was commonly performed using automated fractionation
machines, but it was also performed manually in cases of
morphologic abnormalities. The neutrophil and lymphocyte counts
were calculated as the total WBC multiplied by the percentage of
each. Meanwhile, NLR was calculated as ANC divided by ALC.Table 2

































ANC, absolute neutrophil count; ALC, absolute lymphocyte count; ER, estrogen receptor; H
ductal carcinoma; PR, progesterone receptor; TNBC, triple negative breast cancer.Statistical analysis
Categorical variables were compared using Chi-square test or
Fisher’s exact test. Student’s t-test was used to compare means.
Clinical-pathologic factors associated with LPBC were analyzed
using the logistic regression analysis. The variables showing a sta-
tistical significance in the univariate analysis were entered in the
multivariable analysis.
To evaluate the ability of the ANC to predict LPBC, we deter-
mined the area under the curve (AUC) using receiver operating
characteristic (ROC) curves with Delong method [26]. The ROC
curves were constructed to assess the diagnostic performance of
ANC and other clinical parameters, and the AUCs were calculated
and compared. We also performed net reclassificationMultivariable analysis
p value ORs (95% CIs) p value




















ER-2, human epidermal growth factor receptor-2; HG, histologic grade; IDC, invasive
Fig. 2. Comparisons of AUC to evaluate an improvement of predicting ability of
multivariable models with Delong method The AUC of the reference model was
0.845. When ANC was added to the model, the AUC of the ANC-added model improved
as 0.852. The difference between two models was 0.007 (95% CI, 0.003-0.016) and
showed a trend to significance (P¼ 0.1691). Then the integrated discrimination
improvement (IDI) and net reclassification improvement (NRI) were calculated. The
diagnostic performance was significantly improved by adding ANC to the baseline
model for predicting LPBC according to the IDI and NRI (NRI, P¼ 0.0001; IDI,
P¼ 0.0069, respectively).
C.I. Yoon et al. / The Breast 50 (2020) 141e148144improvement (NRI) and integrated discrimination improvement
(IDI) to analyze the degree to which the addition of ANC to the
reference model improved its predictive ability [27].
Pearson’s Correlation coefficient was calculated to measure the
correlative value between continuous TIL levels and markers of
peripheral blood cell counts. The interaction between TIL and ANC,
and major pathological parameters was tested at a significance
level of 0.10. All statistical tests were two-tailed, and p< 0.05 was
considered statistically significant and 0.05 p< 0.2 was consid-
ered a trend toward significance to increase the sensitivity to detect
potential selection bias. All statistical analyses were performed
using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) and SPSS
version 23.0 (SPSS, Chicago, IL, USA).
Results
Baseline characteristics
A total of 810 patients were included in this study. The median
patient age was 51 (24e91) years for the all patients. The mean
value and standard deviation of TIL in all patients were
23.95± 25.52. The mean values of ANC, ALC, and NLR were 3.60 (K/
mL), 1.98 (K/mL), and 1.68, respectively. The patients were divided
into the LPBC and non-LPBC groups according to the TIL level. In
total, 132 (16.3%) patients had LPBC, and 678 (83.7%) patients had
non-LPBC.
In Table 1, the patients with ductal carcinoma had a higher rate
of LPBC compared to the patients with non-ductal carcinoma
(P< 0.001). Also, the LPBC group had higher rates of high HG
(P< 0.001), negative ER (P< 0.001), negative PR (P< 0.001), high
Ki67 expression, and HER2 overexpression (P< 0.001). In addition,
the rates of breast cancer subtypes were significantly different
between the two groups; the LPBC group had higher proportions of
HER2-positive and TNBC subtypes than the non-LPBC group
(P< 0.001). Meanwhile, other characteristics including age and
anatomical tumor burden such as T stage, N stage, and AJCC stage
did not differ between two groups.
The LPBC group had lower mean of ANC
When we compared means of peripheral blood count between
LPBC and non-LPBC, the mean ANC of the LPBC group was signifi-
cantly lower than that of the non-LPBC (P¼ 0.023; Fig. 1A). How-
ever, means of ALC and NLR did not differ between two groups
(Fig. 1B, P¼ 0.528; Fig. 1C, P¼ 0.099, respectively). Then, we per-
formed further analyses on the relationship between ANC and
LPBC.
Multivariable models for LPBC with ANC
To investigate an independent value of ANC to predicting LPBC,
we performed multivariable analyses. First, in the univariate anal-
ysis, the significant variables were ANC, histology, subtypes, Ki-67
expression, HG, ER, PR, and HER2 using logistic regression ana-
lyses (Table 2). Because subtypes were reflected on ER, PR, and
HER2 status, only subtype was included in the multivariable model
to avoid collinearity of variables. In multivariable model, contin-
uous ANC remained an independent variable associated with LPBC
(OR: 0.790, 95% CI: 0.642e0.971, P¼ 0.025; Table 2), indicating that
the probability of LPBC is reductive of 21.0% according to the in-
crease of ANC as 1,000 unit.
To evaluate an improvement of predicting ability of multivari-
able models with ANC, we compared the AUCs among the models
using ROC curves with Delong method (Fig. 2). The AUC of the
referencemodel was 0.845.When ANCwas added to themodel, theAUC of the ANC-added model improved as 0.852. The difference
between twomodels was 0.007 (95% CI,0.003-0.016) and showed
a trend to significance (P¼ 0.1691, Fig. 2).
Then the IDI and NRI were calculated because they are in-
dicators of improvements following reclassification in a nested
model and can determine whether the predictive power of a
combination of traditional factors is improved upon ANC inclusion.
We found that the diagnostic performance was significantly
improved by adding ANC to the baseline model for predicting LPBC
according to the IDI and NRI (NRI, P¼ 0.0001; IDI, P¼ 0.0069,
respectively, Fig. 2).
Correlation between TILs and ANC in the subgroups according to
interaction effects
Next we evaluated the correlation between two continuous
variables using Pearson’s correlation analysis. A trend for veryweak
inverse correlation was observed between TIL levels and ANC
(Pearson’s r¼0.057, P¼ 0.105; Fig. 3A). Since TIL levels are largely
affected by biological characteristics, we performed a linear
regression model to investigate interaction effects in the correla-
tion between TIL levels and ANC among the subgroups.
The effects of an interaction between TIL levels and ANC were
C.I. Yoon et al. / The Breast 50 (2020) 141e148 145tested according to the pathological factors at an alpha level of 0.10.
The P-values of tests for an interaction effect between two markers
were significant in relation to ER status, Ki67 expression, and HG
(Table 3). Among the subgroups divided by these results, a signif-
icant inverse correlation between TIL levels and ANCwas noticed in
the group with negative ER or high Ki67 expression though the
correlation was quite weak (Fig. 3B and C, respectively). Also, a
trend for negative correlation between two markers was recog-
nized in the group with HG of 3 (Fig. 3D). Furthermore, four-way
interaction test among ANC, TIL levels, ER status, Ki67 expression,
and HG showed a statistical significance. When these markers were
combined, an inverse correlation between TIL and ANC was slightly
increased in patients with ER-negative, high Ki67, and HG of 3
(Pearson’s r¼0.2867, P-value¼ 0.0239; Fig. 4A). Also, the AUC of
ANC was 0.671 (0.532e0.809) in predicting TIL levels (P¼ 0.0157,
Fig. 4B).Discussion
In this study, we investigated whether peripheral blood cell
counts were associated with LPBC. We hypothesized that TILs were
associated with blood cell counts, which reflect local and hostFig. 3. Pearson correlation analyses between TIL and ANC. (A) A trend for very weak in
r¼0.057, P¼ 0.105). The P-values of tests for an interaction effect were significant in relat
was 0.1786 (P¼ 0.0341) (C) In the subgroup with high Ki67, Pearson’s rwas 0.1243 (P¼ 0.immunity, respectively. We found a significantly reduced mean
ANC in those with LPBC compared to those with non-LPBC. More-
over, continuous ANC was a significant predictive factor of LPBC,
independent of the cancer subtypes and other related variables.
The increase of ANC as 1K unit could be estimated as reduced by
21% in predicting LPBC. In addition, in the subgroups identified by
interaction tests, we found a linear inverse correlation between TILs
and ANC.
The negative correlation observed between high ANC and LPBC
in our study is supported by the fact that neutrophils may act
against the immune system via several mechanisms. Experimental
data suggested that neutrophils could suppress the cytolytic ac-
tivity of lymphocytes, natural killer cells, and activated T-cells when
it is co-cultured with lymphocytes form normal healthy donor.
Also, activated neutrophils have been reported to secrete myelo-
peroxidase, resulting in the suppression of lymphocyte function
[28].
Moreover, tumor-associated neutrophils might influence local
tumor immunity and tumor progression by regulating the tumor
microenvironment. The enzymatic activity of neutrophils has been
found to promote remodeling of the extracellular matrix, which
results in the release of basic fibroblast growth factor andmigrationverse correlation was observed between TIL levels and ANC in all patients (Pearson’s
ion to ER status, Ki67 expression, and HG (B) In the ER-negative subgroup, Pearson’s r
0389) (D) In the subgroup with histologic grade 3, Pearson’s rwas 0.1780 (P¼ 0.0581).
Table 3
Linear regression analysis using interaction and subgroup analysis.





























ER, estrogen receptor; HER-2, human epidermal growth factor receptor-2; HG,
histologic grade; IDC, invasive ductal carcinoma; PR, progesterone receptor; TNBC,
triple negative breast cancer.
C.I. Yoon et al. / The Breast 50 (2020) 141e148146of either endothelial cells or tumor cells [28,29]. The modulated
tumor microenvironment might contribute to tumor growth and
acquisition of metastatic capability. Specifically, neutrophil-derived
oncostatin M stimulates cancer cells to secrete vascular endothelial
growth factor and increases invasiveness in breast cancer [30].
It is well known that LPBC was associated with the cancer
subtypes [15,22,31]. The different rates of LPBC according to the
subtypes was reproducible in our study; specifically, the rate of
LPBC was higher in the HER2 and TNBC subtypes are than that in
the luminal/HER2-negative subtype. Another notable finding was
that the Ki-67 labelling index was correlated with LPBC, which mayFig. 4. Pearson correlation analysis and ROC curve between ANC and TILs in patients
value¼ 0.0239). (B) The AUC of ANC in predicting TIL levels was 0.671 (95% CI, 0.532e0.80be explained by the fact that tumors with high Ki-67 labelling index
were more frequent in the HER2 or TNBC subtypes. These findings
provide evidence that our data is reliable.
Clinically, a previous study showed that high ANC could be a
poor prognostic marker in patients with TNBC [5]. This finding is
consistent with our result in that high ANC may negatively impact
TILs while high TILs are associated with a good prognosis in this
aggressive subset of breast cancer [32]. In this study, the association
between NLR and TILs was not identified, although NLR is a well-
known poor prognostic marker in various cancers including
breast cancer [1,6e10]. The relationship between NLR and TILs
warrants further research.
Interestingly, emerging evidence suggests that high ANC could
be a negative predictor of response to immune checkpoint in-
hibitors (ICI) for cancer such as lung cancer and melanoma
[11,33,34]. By contrast, high TILs are positive predictors of treat-
ment response to ICI [35,36]. Contrasting responses to ICI according
to high ANC and TILs indirectly support our results, but further
studies are still needed to clearly establish the predictive value of
TILs in the treatment response to ICI.
There is an another study evaluating the relationships between
peripheral blood cell counts and CD8þ TILs, which are in line with
an interest of our study [37]. Contrast to our study, they specifically
addressed cytotoxic T-cells with CD8 using core-biopsy samples
and found associations of CD8þ TILs with ALC and AMC. However, it
is in line with our study that peripheral blood counts as systemic
immunemarkers are linked with TILs as local one. Intensive studies
are warranted regarding the relationships between immune
element of tumor and those of host system using more specific
labelling markers.
This study also has some limitations, including the absence of
survival analyses due to short-term follow-up. Assessment of the
clinical outcomes of the study population might have helped to
specify the prognostic capability of these biomarkers. Another
limitation is that neutrophil and lymphocyte counts may vary ac-
cording to individual physiological and pathological processes such
as infectious condition. The association between NLR and TILs in
breast cancer warrants further research. Also, the tumor-infiltrating
neutrophil should be identified and characterized by specific
markers in relation to ANC or NLR in future study. Despite these
limitations, we found relevant evidence showing specific correla-
tions between LPBC and ANC, providing scientific insight on the
host-tumor immune interaction in breast cancer.with ER-negative, high Ki67, and HG of 3 (n¼62) (A) Pearson’s r was 0.2867 (P-
9; P¼ 0.0157).
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Low peripheral ANC could be associated with LPBC, supporting
the hypothesis that systemic immune cell counts might affect the
tumor-immune microenvironment. A possible association between
peripheral ANC and tumor-associated neutrophil reflecting the
tumor microenvironment should be studied.
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